Skip to Main Navigation
Skip to Page Content

Nomination Summary for Hydralazine hydrochloride (N97014)

Nominated Substances: Hydralazine hydrochloride

Nomination Date: 06/02/1997

Nominator: Private Individual

Rationale: Hydralazine hydrochloride is used in various antihypertensive drug formulations for which several million prescriptions are written annually. It is suspected of being a carcinogen based on mutagenicity data and positive mutagenicity and carcinogenicity data in animals for structurally related compounds. There is a lack of complete and adequate 2-year bioassay data for hydralazine hydrochloride.

NTP Principles: not specified

Status: In Review/Pending

Agents and Status

The following information relates to the specific agent and may include history from earlier or later nominations for this same agent.

CASRN: 304-20-1

Agent Name: Hydralazine hydrochloride

  • No studies are available.